Unlocking Multiple Mechanisms of Action Using a Unique AI/ML Platform with Novel Immunomodulators for ARDS Patients
Time: 8:45 am
day: Day Two
Details:
- Highlighting the lead compound is Phase 2 ready for ARDS patients (including COVID-ARDS) having completed Phase 1
- Using the unique AI/ML platform to develop 21 next generation p38 alpha/MK2 novel immunomodulators
